News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , May 22, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before underwriting discounts and commissions, for gross proceeds of
View HTML
Toggle Summary Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
FREMONT, Calif. , May 21, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced it has entered into a $50.0 million senior secured term loan facility with Solar Capital Ltd. and the Life Sciences Group at Bridge Bank , a division of Western Alliance Bank .
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , May 21, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common stock. All of the shares to be sold in the offering will be offered by Ardelyx .
View HTML
Toggle Summary Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
On Track to Submit NDA for Tenapanor in IBS-C in Second Half of 2018 Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia FREMONT, Calif. , May 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the first
View HTML
Toggle Summary Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
License Agreement Advances First-in-Class Tenapanor for IBS-C and Hyperphosphatemia in Canada Ardelyx to Receive Up to CAD 25 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , March 19, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced a license agreement with
View HTML
Toggle Summary Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS-C on Track for Submission in Second Half of 2018 FREMONT, Calif. , March 14, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported pipeline highlights and financial results for
View HTML
Toggle Summary Ardelyx Announces Departure of Chief Scientific Officer
FREMONT, Calif. , Feb. 12, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell , Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018 , to pursue a position as chief executive officer of an early stage biotech start-up company
View HTML
Toggle Summary Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
FREMONT, Calif. , Feb. 8, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00 p.m. ET on Thursday, Feb.
View HTML
Toggle Summary Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference
FREMONT, Calif. , Jan. 3, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, 2018 at 10 a.m. PT .
View HTML
Toggle Summary Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Favorable Tolerability Profile Demonstrated in 1-year Safety Study FREMONT, Calif. , Jan. 3, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of
View HTML